A UCL Technology Fund investment,  MeiraGTx Holdings plc, a vertically integrated, clinical stage gene therapy company, has raised $75 million of gross proceeds upon close of the company’s initial public offering (IPO) on June 12 2018, selling 5,000,000 shares at a public offering price of $15.00 per share.  The shares are listed on the Nasdaq Global Select Market.

The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation company, and is dedicated to bringing UCL’s world-class research in life and physical sciences to commercial reality. MeiraGTx is its first investment to IPO. MeiraGTx has strong roots in UCL; its rare eye diseases business was borne out of the laboratories of Professor Robin Ali, a human molecular genetics expert at the UCL Institute of Ophthalmology, a world leader in ocular gene therapy.